Author Affiliations: Department of Medicine (Dr Berkowitz) and Division of Nephrology (Dr Johansen), University of California, San Francisco; and Nephrology Section, San Francisco VA Medical Center (Dr Johansen), San Francisco.
We wish to thank Lavoie and colleagues for their thoughtful letter. We agree with their suggestion that interventions in behavioral medicine be viewed analogously to phase 1, 2, and 3 clinical trials in drug development and thank them for pointing out the recommendations of the Office of Behavioral and Social Science Research.
Berkowitz SA, Johansen KL. Behavioral Medicine Trial Design: Time for a Change—Reply. Arch Intern Med. 2012;172(17):1350-1351. doi:10.1001/archinternmed.2012.3223